false
Catalog
Clozapine in the Elderly and Those with Medical Co ...
Presentation Slides
Presentation Slides
Back to course
Pdf Summary
The document discusses the use of clozapine in elderly patients with schizophrenia and medical comorbidity, as well as the management of care transitions. It highlights that elderly patients can be safely started on clozapine and outlines common principles for treating those at higher risk for adverse events, such as adjusting titrations and minimizing drug interactions. The document also addresses concerns specific to the elderly population, including reduced serum albumin levels, increased volume of distribution, and age-related decline in CYP 1A2 activity.<br /><br />Retrospective data is presented showing that clozapine is well tolerated in elderly patients and can lead to lower psychiatric hospitalization rates. The document also discusses clozapine dosing in the elderly, noting that median doses are lower compared to younger patients and the ratio of clozapine to norclozapine is higher.<br /><br />The document emphasizes the importance of managing clozapine titration in the elderly, taking into account kinetic and pharmacodynamic drug-drug interactions, and the need to aggressively manage constipation. It also discusses the effects of CYP inhibitors and inducers on clozapine levels and provides a list of common inhibitors and inducers.<br /><br />Furthermore, the document addresses the prevention of ileus, minimizing orthostasis and sedation, and the rechallenge of high-risk patients. It provides recommendations for managing anticholinergic medications and other constipating medications. Additionally, it discusses the approach to rechallenging patients with a history of seizures, diabetic ketoacidosis, myocarditis, cardiomyopathy, priapism, venous thromboembolism, and laboratory abnormalities.<br /><br />The document concludes by highlighting the importance of improving acceptance of clozapine and effective communication during care transitions. It suggests discussing the benefits of clozapine treatment, using finger-stick POC devices for ANC monitoring, and not removing prior antipsychotics too quickly. Finally, it emphasizes that elderly patients should not be deprived of a clozapine trial based on age and that adjustments in dosing and medication management are necessary.
Keywords
clozapine
elderly patients
schizophrenia
medical comorbidity
care transitions
adverse events
titrations
drug interactions
psychiatric hospitalization rates
dosing
Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
×
Please select your language
1
English